Back to Search
TIMOTHY CALL, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1326024829Individual
Specialties, Licenses & Credentials
Hematology (Internal Medicine) Physician
Internal Medicine — Hematology
Code: 207RH0000X
33385(MN)
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
33385(MN)
Research & Publications (20)
Validation of a new prognostic index for patients with chronic lymphocytic leukemia.
PMID 19090008·Cancer·2009
4-observational
The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia.
PMID 18656259·Leuk Res·2009
8-other
B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome.
PMID 19015397·Blood·2009
8-other
Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia.
PMID 19470922·J Clin Oncol·2009
3-trial
Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia.
PMID 19604237·Br J Haematol·2009
3-trial
Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia.
PMID 19255329·J Clin Oncol·2009
8-other
Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia.
PMID 19620484·J Clin Oncol·2009
4-observational
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.
PMID 19008456·Blood·2009
3-trial
Nosocomial contamination of laryngoscope handles: challenging current guidelines.
PMID 19608822·Anesth Analg·2009
8-other
N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia.
PMID 19373657·Leuk Lymphoma·2009
3-trial
Risk of non-Hodgkin lymphoma in association with germline variation in complement genes.
PMID 19344414·Br J Haematol·2009
8-other
Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab.
PMID 18584865·Leuk Res·2008
3-trial
Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.
PMID 18759253·Cancer·2008
3-trial
Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia.
PMID 18384436·Br J Haematol·2008
8-other
The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma.
PMID 18373706·Br J Haematol·2008
8-other
MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or= 5 x 10(9) L(-1) but a B-cell lymphocyte count <5 x 10(9) L(-1)?
PMID 18179821·Leuk Res·2008
8-other
Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia.
PMID 18203011·Leuk Lymphoma·2008
8-other
CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential.
PMID 18275431·Br J Haematol·2008
8-other
Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma.
PMID 18990758·Cancer Epidemiol Biomarkers Prev·2008
8-other
Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients.
PMID 18064298·J Clin Invest·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 200 1ST ST SW
ROCHESTER, MN 55905 - Phone
- (507) 284-2511
Quick Facts
- NPI
- 1326024829
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile